FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
SeaStar Medical Holding Corporation Stock AnalysisComprehensive stock analysis for SeaStar Medical Holding Corporation (ICU) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisICU
ICU
SeaStar Medical Holding Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ICU
Home🔹Stocks🔹SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation

ICU•NASDAQ

SeaStar Medical Holding Corporation

ICU•NASDAQ
Market cap
$9.76M
Sentiment

Your view on ICU

Mkt Cap
$9.76M
Sentiment
Your view
ICU
SeaStar Medical Holding Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ICU
Company Overview

Overview

What the company does, where it operates, and who runs it.

About SeaStar Medical Holding Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Eric Schlorff
Headquarters
3513 Brighton Boulevard, Denver, CO, US
Industry
Biotechnology
Sector
Healthcare
CEO
Eric Schlorff
Headquarters
3513 Brighton Boulevard, Denver, CO, US
Description

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News